BioMarin Pharmaceutical Inc. Book value per Share

Book value per Share of BMRN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Book value per Share growth rates and interactive chart. Book value per common share (or, simply book value per share - BVPS) is a method to calculate the per-share value of a company based on common shareholders' equity in the company. Should the company dissolve, the book value per common share indicates the dollar value remaining for common shareholders after all assets are liquidated and all debtors are paid. It is calculated as Total Shareholder's Equity minus Preferred Equity and divided by the number of shares outstanding.


Highlights and Quick Summary

  • Book value per Share for the quarter ending March 31, 2022 was 23.87 (a 2.57% increase compared to previous quarter)
  • Year-over-year quarterly Book value per Share increased by 2.87%
  • Annual Book value per Share for 2021 was 23.34 (a 2.88% increase from previous year)
  • Annual Book value per Share for 2020 was 22.69 (a 30.07% increase from previous year)
  • Annual Book value per Share for 2019 was 17.44 (a 4.01% increase from previous year)
Visit stockrow.com/BMRN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Book value per Share of BioMarin Pharmaceutical Inc.

Most recent Book value per Shareof BMRN including historical data for past 10 years.

Interactive Chart of Book value per Share of BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. Book value per Share for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 23.87
2021 23.27 23.28 23.2 22.9 23.34
2020 22.71 22.38 17.91 18.01 22.69
2019 17.44 17.15 16.54 16.47 17.44
2018 16.76 16.42 16.31 15.96 16.77
2017 16.1 16.07 16.03 16.03 16.14
2016 16.67 15.78 11.79 14.18 16.67
2015 15.0 14.25 14.69 15.39 15.0
2014 10.44 10.26 10.01 10.14 10.44
2013 9.74 9.07 9.03 9.77 9.74
2012 8.45 8.22 8.48 6.71 8.45
2011 6.89 6.9 6.59 6.89

Business Profile of BioMarin Pharmaceutical Inc.

Sector: Healthcare
Industry: Biotechnology
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.